Sharmila Patel

1.9k total citations · 1 hit paper
23 papers, 1.3k citations indexed

About

Sharmila Patel is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Sharmila Patel has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Sharmila Patel's work include Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Treatment and Pharmacology (2 papers). Sharmila Patel is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Treatment and Pharmacology (2 papers). Sharmila Patel collaborates with scholars based in United States, United Kingdom and Japan. Sharmila Patel's co-authors include Steven K. Hanks, Marion C. Harper, Mihail CALALB, Mark R. Player, Jun Suzuki, Roger M. Mason, Takashi Kamimura, Roger S. Buxton, Yoshihiko Sumi and Zhi Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Sharmila Patel

20 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin.

1992 714 citations Steven K. Hanks, Mihail CALALB et al. Proceedings of the National Academy of Sciences profile →

Peers

Sharmila Patel

ONCOL

IMMUN

Eloise C. Anthony Netherlands

Michelle L. Matter United States

Jaume Piulats Spain

Federico Galvagni Italy

Andreas Herrlich United States

Yuichi Mazaki Japan

Michael Leserer Germany

Pengcheng Zhou China

Takaya Gotoh Japan

Kristin Roovers United States

Eloise C. Anthony Netherlands

Sharmila Patel

967 ×1.6

385 ×0.7

473 ×1.3

177 ×0.8

ONCOL

535 ×3.2

IMMUN

Citations per year, relative to Sharmila Patel Sharmila Patel (= 1×) peers Eloise C. Anthony

Countries citing papers authored by Sharmila Patel

Since Specialization

Citations

This map shows the geographic impact of Sharmila Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharmila Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharmila Patel more than expected).

Fields of papers citing papers by Sharmila Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharmila Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharmila Patel. The network helps show where Sharmila Patel may publish in the future.

Co-authorship network of co-authors of Sharmila Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Sharmila Patel. A scholar is included among the top collaborators of Sharmila Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharmila Patel. Sharmila Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nooka, Ajay K., Jonathan L. Kaufman, César A. Rodríguez, et al.. (2024). Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British Journal of Haematology. 204(6). 2227–2232.

Anderson, Larry D., Alfred Chung, Chakra P. Chaulagain, et al.. (2024). Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups. Blood. 144(Supplement 1). 675–675. 1 indexed citations

Tao, Ran, et al.. (2022). Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer. 22(1). 901–901. 16 indexed citations

Rodriguez, Cesar, Jonathan L. Kaufman, Jacob P. Laubach, et al.. (2022). Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.. Journal of Clinical Oncology. 40(16_suppl). 8011–8011. 4 indexed citations

Tao, Ran, et al.. (2022). Patient Characteristics Associated with Dose Modifications for VRd Among Newly Diagnosed Multiple Myeloma Patients. Future Oncology. 18(36). 3983–3991. 2 indexed citations

Fu, Alex Z., et al.. (2022). Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology. 40(16_suppl). 8039–8039. 1 indexed citations

Tao, Ran, et al.. (2021). Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy. Blood. 138(Supplement 1). 3782–3782.

Shah, Nina, Sharmila Patel, Huiling Pei, et al.. (2021). Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.. Journal of Clinical Oncology. 39(15_suppl). TPS8054–TPS8054. 3 indexed citations

Patel, Sharmila, et al.. (2019). Initial surgical and clinical experience with the Nucleus CI532 slim modiolar electrode in the UK. Cochlear Implants International. 20(4). 207–216. 23 indexed citations

10.

Patch, Raymond J., Hui Huang, Sharmila Patel, et al.. (2017). Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents. European Journal of Medicinal Chemistry. 138. 830–853. 30 indexed citations

11.

Meegalla, Sanath K., Hui Huang, Carl R. Illig, et al.. (2016). Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(17). 4216–4222. 11 indexed citations

12.

Patel, Sharmila & Mark R. Player. (2009). Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease. Current Topics in Medicinal Chemistry. 9(7). 599–610. 98 indexed citations

13.

Kreutter, K. D., Tianbao Lu, Lily Lee, et al.. (2008). Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. Bioorganic & Medicinal Chemistry Letters. 18(9). 2865–2870. 24 indexed citations

14.

Patel, Sharmila & Mark R. Player. (2008). Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opinion on Investigational Drugs. 17(12). 1865–1882. 82 indexed citations

15.

Patel, Sharmila, et al.. (2006). Inhibitory Effect of Statins on Renal Epithelial-to-Mesenchymal Transition. American Journal of Nephrology. 26(4). 381–387. 40 indexed citations

16.

Patel, Sharmila, Jun Suzuki, Atsushi Imaizumi, et al.. (2005). RhoGTPase Activation Is a Key Step in Renal Epithelial Mesenchymal Transdifferentiation. Journal of the American Society of Nephrology. 16(7). 1977–1984. 64 indexed citations

17.

Patel, Sharmila, Roger S. Buxton, Jun Suzuki, et al.. (2004). Oncostatin M, a Cytokine Released by Activated Mononuclear Cells, Induces Epithelial Cell-Myofibroblast Transdifferentiation via Jak/Stat Pathway Activation. Journal of the American Society of Nephrology. 15(1). 21–32. 105 indexed citations

18.

Patel, Sharmila, et al.. (2001). Paradoxical embolus: an unusual indication for upper limb amputation.. PubMed. 83(6). 386–7.

19.

Price, Richard, Sharmila Patel, Ian Chivers, Peter Milligan, & Sarah A. Taylor. (1999). Early Markers of Nephrotoxicity: Detection of Children at Risk from Environmental Pollution. Renal Failure. 21(3-4). 303–308. 13 indexed citations

20.

Hanks, Steven K., Mihail CALALB, Marion C. Harper, & Sharmila Patel. (1992). Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin.. Proceedings of the National Academy of Sciences. 89(18). 8487–8491. 714 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact